Navigation Links
FDA Approves First Ceramic-on-Metal Total Hip Replacement System
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved on June 13 the first ceramic-on-metal total artificial hip system for patients with osteoarthritis.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Hip joints consist of bone in the shape of a ball at the top of the thighbone (femur) that fits into a rounded socket in the pelvis (acetabulum).  During total hip replacement surgery, worn and damaged portions of bone and cartilage are removed and replaced with an artificial hip joint.

Specifically, a shell or cup replaces the socket, a stem is inserted into the thighbone and a femoral head or ball at the top of the stem is fitted inside the curved artificial socket where the ball can slide around, allowing for movement.

Previous total hip replacement systems cleared or approved by FDA have used different combinations of metal, ceramic, and polyethylene (a form of plastic). The Pinnacle CoMplete Acetabular Hip System is the first to combine a ceramic ball and a metal socket.

"Orthopedic surgeons and their patients now have an additional option for total hip replacement with the approval of the Pinnacle CoMplete Acetabular Hip System," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health.

The FDA's approval is based on a two-year, randomized clinical trial, which found no clinical difference between 194 patients who received the new ceramic-on-metal system and 196 patients in a control group who received a metal-on-metal hip implant. Two patients who received the Pinnacle CoMplete system required a second surgery to replace their new implant compared with three patients who required a second surgery in the control group.

As a condition of FDA approval, the manufacturer, DePuy Orthopaedics Inc., will conduct a
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... 19, 2014  For Cloud Pharmaceuticals, Inc., a ... development, partnering is an integral part of its ... new drugs and identify early stage, preclinical, IND, ... their development. The company also partners with funds ... business model, Cloud Pharmaceuticals will be participating in ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Calif., Jan. 27, 2011 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... release unaudited financial results for the quarter ended December ... 2011.  Keith Katkin, President and Chief Executive Officer, Randall ... and Christine Ocampo, Vice President, Finance, will host an ...
... SAN DIEGO, Jan. 27, 2011 Profil™ Institute for ... early phase clinical trials for diabetes and obesity, announced ... speaker at the Ramanbhai Foundation 5th International Symposium and ... The Ramanbhai Foundation,s International Symposium will be ...
Cached Medicine Technology:Profil Institute's CEO Presenting on Early Phase Clinical Research in India 2Profil Institute's CEO Presenting on Early Phase Clinical Research in India 3
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 The ... help businesses and manufacturers perform tests on items ranging ... an increasingly regulated society, pressure on operators to ensure ... than ever. A greater number of government safety regulations ... manufacturers' goods prior to sale. Although revenue briefly dipped ...
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... Discount-Dress.com, a company that ... announced its decision to implement a new shopping cart ... ladies across the world. Furthermore, the company has unveiled ... , The new items come in fashionable designs; ... up to 56 percent off. "We are happy to ...
(Date:9/21/2014)... Rio, Colorado (PRWEB) September 21, 2014 ... Colorado, ten teams of disabled and able-bodied athletes rafted ... and completed a ropes course in pursuit of outdoor ... from national non-profit World T.E.A.M. Sports, disabilities proved ... athletes who successfully completed the three stage event. , ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... smoke. According to a recent study researchers find smoking during ... having a baby with a cleft lip. ,The study, ... their babies were about six months old. Researchers asked about ... many cigarettes she smoked and whether she was exposed to ...
... of osteoarthritis the major cause of disability in ... a few weeks // say researchers according to ... in Europe and the United States recommend the ... to relieve osteoarthritis pain. ,Researchers explain many ...
... could be the first step in the path for a ... first time they have found a successful way to deliver ... mouse. ,Gene therapy for muscular dystrophy has been ... the whole body has been a major obstacle for scientists. ...
... drug for the treatment of alcohol dependence. But one of ... which can reduce medication compliance and can be absorbed // ... injection of naltrexone and the benefit of its use for ... they were randomly assigned to get an injection of naltrexone ...
... clinical trial of people infected with both HIV and hepatitis ... their study, patients who are treated with a newer combination ... of HCV than those who receive standard therapy. ,The ... estimated 1 million Americans infected with HIV also have HCV, ...
... low-fat salad dressing anymore. New research shows fats actually ... ,Researchers studied men and women between ages 19 ... with salad dressing that contained zero, six or 28 ... 11 hours following each meal. ,Results showed that ...
Cached Medicine News:
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: